Vivus (VVUS -14.6%) adds to the losses it saw yesterday afternoon following the release of...

|By:, SA News Editor

Vivus (VVUS -14.6%) adds to the losses it saw yesterday afternoon following the release of troubling safety data related to its Qnexa drug. Not helping is a downgrade to Market Perform from Leerink Swann; the firm thinks investors should be careful, given a lack of information on the FDA's standards for acceptable birth defect risk, and believes "there are more downside risks than upside potentials" over the next several quarters.